NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT07062965 2026-04-16
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT04852887 2026-04-15
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT05827081 2026-04-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT05774951 2026-04-13
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06492616 2026-03-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT06428396 2026-03-24
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting